Nimotuzumab
- Generic Name
- Nimotuzumab
- Drug Type
- Biotech
- CAS Number
- 780758-10-3
- Unique Ingredient Identifier
- 6NS400BXKH
- Indication
Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
- Associated Conditions
- Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Drug: RT plus Cisplatin
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 381
- Registration Number
- NCT04456322
- Locations
- 🇨🇳
Sun Yat-sen Universitty Cancer Center, Guangzhou, Guangdong, China
A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma
- Conditions
- Oral Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Xin-Hua Xu
- Target Recruit Count
- 68
- Registration Number
- NCT04367909
- Locations
- 🇨🇳
Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University, Yichang, Hubei, China
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
- Conditions
- ChemoradiotherapyEsophageal CancerUnresectable Malignant NeoplasmNimotuzumab
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2024-05-16
- Target Recruit Count
- 55
- Registration Number
- NCT04207918
- Locations
- 🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China
Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 47
- Registration Number
- NCT03915132
- Locations
- 🇨🇳
Cancer hospital, Chinese Academy of Medical Sciences, Beijin, China
Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsNasopharyngeal DiseasesHead and Neck Neoplasm
- Interventions
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 384
- Registration Number
- NCT03837808
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Target Recruit Count
- 45
- Registration Number
- NCT03766178
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 67
- Registration Number
- NCT03666221
- Locations
- 🇨🇳
Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China
Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Target Recruit Count
- 54
- Registration Number
- NCT03620032
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Phase II Umbrella Study Directed by Next Generation Sequencing
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 400
- Registration Number
- NCT03574402
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Guiyang Medical University
- Target Recruit Count
- 180
- Registration Number
- NCT03557112
- Locations
- 🇨🇳
Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.